Sickle cell disease: Role of reactive oxygen and nitrogen metabolites

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 9, 2007, Pages 926-932

  Wood, Katherine C ^a   Granger, D Neil ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Auto oxidation; Haemoglobin; Hydroxyl radical; NADPH oxidase; Nitric oxide; Peroxynitrite; Superoxide; Tetrahydrobiopterin; Vaso occlusion; Xanthine oxidase

Indexed keywords

APOCYNIN; APOLIPOPROTEIN A1; CATALASE; DEFERIPRONE; DEFEROXAMINE; HYDROXYUREA; IRON CHELATING AGENT; NITRIC OXIDE SYNTHASE; POLYNITROXYL ALBUMIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SALAZOSULFAPYRIDINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ADRENERGIC SYSTEM; ARTERIOLE; AUTOOXIDATION; BLOOD CELL; CELL ADHESION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEMOLYSIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SICKLE CELL ANEMIA; VASCULAR DISEASE;

ANEMIA, SICKLE CELL; ANIMALS; ANTIOXIDANTS; ANTISICKLING AGENTS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ERYTHROCYTE AGGREGATION; HEMOGLOBIN, SICKLE; HEMOLYSIS; HUMANS; HYDROXYUREA; IRON CHELATING AGENTS; LEUKOCYTE ROLLING; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PLATELET ADHESIVENESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; VASODILATION; XANTHINE OXIDASE;

EID: 34447513984     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04639.x     Document Type: Review

References (85)

1. Nath KA, Grande JP, Haggard JJ et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am. J. Pathol. 2001 158 : 893 903.
2. Hebbel RP. Special issue of microcirculation: Examination of the vascular pathobiology of sickle cell anemia. Microcirculation 2004 11 : 99 100.
3. Hiran S. Multiorgan dysfunction syndrome in sickle cell disease. J. Assoc. Physicians India 2005 53 : 19 22.
4. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 2000 106 : 411 20.
5. Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am. J. Physiol. Heart Circ. Physiol. 2004 287 : H293 301.
6. Aslan M, Ryan TM, Adler B et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc. Natl Acad. Sci. USA 2001 98 : 15 15 20.
7. Sorescu D, Weiss D, Lassegue B et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002 105 : 1429 35.
8. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 2003 4 : 51 61.
9. Ishikawa M, Stokes KY, Zhang JH, Nanda A, Granger DN. Cerebral microvascular responses to hypercholesterolemia: Roles NADPH oxidase P-selectin. Circ. Res. 2004 94 : 239 44.
10. Chan AC, Chow CK, Chiu D. Interaction of antioxidants and their implication in genetic anemia. Proc. Soc. Exp. Biol. Med. 1999 222 : 274 82.
11. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean? Br. J. Pharmacol. 2004 142 : 231 55.
12. Sess D, Carbonneau MA, Thomas MJ et al. First observations on the main plasma parameters of oxidative stress in homozygous sickle cell disease. Bull. Soc. Pathol. Exot. 1992 85 : 174 9.
13. Hasanato RM. Zinc and antioxidant vitamin deficiency in patients with severe sickle cell anemia. Ann. Saudi Med. 2006 26 : 17 21.
14. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br. J. Haematol. 2006 132 : 108 13.
15. Natta CL, Chen LC, Chow CK. Selenium and glutathione peroxidase levels in sickle cell anemia. Acta Haematol. 1990 83 : 130 2.
16. Reid ME, Badaloo A, Forrester T, Jahoor F. In vivo rates of erythrocyte glutathione synthesis in adults with sickle cell disease. Am. J. Physiol. Endocrinol. Metab. 2006 291 : E73 9.
17. Somjee SS, Warrier RP, Thomson JL, Ory-Ascani J, Hempe JM. Advanced glycation end-products in sickle cell anaemia. Br. J. Haematol. 2005 128 : 112 18.
18. Pritchard KA Jr., Ou J, Ou Z et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am. J. Physiol. Lung Cell Mol. Physiol. 2004 286 : L705 14.
19. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000 96 : 314 20.
20. Nath KA, Shah V, Haggard JJ et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000 279 : R1949 55.
21. Kaul DK, Liu XD, Zhang X, Ma L, Hsia CJ, Nagel RL. Inhibition of sickle red cell adhesion and vaso-occlusion in the microcirculation by antioxidants. Am. J. Physiol. Heart Circ. Physiol. 2006 291 : H167 75.
22. Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 2005 19 : 989 91.
23. Sultana C, Shen Y, Rattan V, Johnson C, Kalra VK. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 1998 92 : 3924 35.
24. Mahaseth H, Vercellotti GM, Welch TE et al. Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. J. Lab. Clin. Med. 2005 145 : 204 11.
25. Hebbel RP, Morgan WT, Eaton JW, Hedlund BE. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc. Natl Acad. Sci. USA 1988 85 : 237 41.
26. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J. Clin. Invest. 1982 70 : 1253 9.
27. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 1985 312 : 159 63.
28. Parks DA, Williams TK, Beckman JS. Conversion of xanthine dehydrogenase to oxidase in ischemic rat intestine: A reevaluation. Am. J. Physiol. 1988 254 : G768 74.
29. Claster S, Chiu DT, Quintanilha A, Lubin B. Neutrophils mediate lipid peroxidation in human red cells. Blood 1984 64 : 1079 84.
30. Benkerrou M, Delarche C, Brahimi L et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002 99 : 2297 303.
31. Agil A, Sadrzadeh SM. Hydroxy-urea protects erythrocytes against oxidative damage. Redox Rep. 2000 5 : 29 34.
32. Jison ML, Munson PJ, Barb JJ et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood 2004 104 : 270 80.
33. Haynes J Jr., Obiako B. Activated polymorphonuclear cells increase sickle red blood cell retention in lung: Role of phospholipids. Am. J. Physiol. Heart Circ. Physiol. 2002 282 : H122 30.
34. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 2006 113 : 1708 14.
35. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc. Natl Acad. Sci. USA 1996 93 : 6770 4.
36. Claster S, Quintanilha A, Schott MA, Chiu D, Lubin B. Neutrophil-induced K+ leak in human red cells: A potential mechanism for infection-mediated hemolysis. J. Lab. Clin. Med. 1987 109 : 201 10.
37. Kuypers FA, Scott MD, Schott MA, Lubin B, Chiu DT. Use of ektacytometry to determine red cell susceptibility to oxidative stress. J. Lab. Clin. Med. 1990 116 : 535 45.
38. Hebbel RP, Leung A, Mohandas N. Oxidation-induced changes in microrheologic properties of the red blood cell membrane. Blood 1990 76 : 1015 20.
39. Berney SI, Ridler CD, Stephens AD, Thomas AE, Kovacs IB. Enhanced platelet reactivity and hypercoagulability in the steady state of sickle cell anaemia. Am. J. Hematol. 1992 40 : 290 4.
40. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J. Lab. Clin. Med. 2001 137 : 398 407.
41. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J. Lab. Clin. Med. 1997 129 : 507 16.
42. Martin CR, Johnson CS, Cobb C, Tatter D, Haywood LJ. Myocardial infarction in sickle cell disease. J. Natl Med. Assoc. 1996 88 : 428 32.
43. Wood KC, Hebbel RP, Granger DN. Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 2004 286 : H1608 14.
44. Bank N, Aynedjian HS, Qiu JH et al. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int. 1996 50 : 184 9.
45. Diwan BA, Gladwin MT, Noguchi CT, Ward JM, Fitzhugh AL, Buzard GS. Renal pathology in hemizygous sickle cell mice. Toxicol. Pathol. 2002 30 : 254 62.
46. Aslan M, Ryan TM, Townes TM et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J. Biol. Chem. 2003 278 : 4194 204.
47. Bank N, Kiroycheva M, Ahmed F et al. Peroxynitrite formation and apoptosis in transgenic sickle cell mouse kidneys. Kidney Int. 1998 54 : 1520 8.
48. Wood KC, Hebbel RP, Lefer DJ, Granger DN. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic. Biol. Med. 2006 40 : 1443 53.
49. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J. Clin. Invest. 2004 114 : 1136 45.
50. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am. J. Physiol. Heart Circ. Physiol. 2000 278 : H1799 806.
51. Huang PL. Endothelial nitric oxide synthase and endothelial dysfunction. Curr. Hypertens. Rep. 2003 5 : 473 80.
52. Brorson JR, Schumacker PT, Zhang H. Nitric oxide acutely inhibits neuronal energy production. The Committees on Neurobiology and Cell Physiology. J. Neurosci. 1999 19 : 147 58.
53. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. J. Biol. Chem. 1992 267 : 24 73 6.
54. Heinzel B, John M, Klatt P, Bohme E, Mayer B. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem. J. 1992 281 : 627 30.
55. Space SL, Lane PA, Pickett CK, Weil JV. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am. J. Hematol. 2000 63 : 200 4.
56. Gladwin MT, Schechter AN, Shelhamer JH et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J. Clin. Invest 1999 104 : 937 45.
57. Meininger CJ, Cai S, Parker JL et al. GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. FASEB J. 2004 18 : 1900 2.
58. Alp NJ, Mussa S, Khoo J et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Invest. 2003 112 : 725 35.
59. Zheng JS, Yang XQ, Lookingland KJ et al. Gene transfer of human guanosine 5′-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation 2003 108 : 1238 45.
60. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001 38 : 1044 8.
61. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 445 50.
62. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000 102 : 2172 9.
63. Lima CS, Arruda VR, Costa FF, Saad ST. Minimal doses of hydroxyurea for sickle cell disease. Braz. J. Med. Biol. Res. 1997 30 : 933 40.
64. Gladwin MT, Rodgers GP. Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet 2000 355 : 1476 8.
65. Koren A, Segal-Kupershmit D, Zalman L et al. Effect of hydroxyurea in sickle cell anemia: A clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr. Hematol. Oncol. 1999 16 : 221 32.
66. Ferguson RP, Arun A, Carter C, Walker SD, Castro O. Hydroxyurea treatment of sickle cell anemia in hospital-based practices. Am. J. Hematol. 2002 70 : 326 8.
67. Steinberg MH, Barton F, Castro O et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003 289 : 1645 51.
68. Kinney TR, Helms RW, O'Branski EE et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999 94 : 1550 4.
69. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am. J. Hematol. 2000 64 : 26 31.
70. Zimmerman SA, Schultz WH, Davis JS et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004 103 : 2039 45.
71. Koren A, Segal-Kupershmit D, Zalman L et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr. Hematol. Oncol. 1999 16 : 221 32.
72. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999 102 : 31 7.
73. Gladwin MT, Shelhamer JH, Ognibene FP et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br. J. Haematol. 2002 116 : 436 44.
74. King SB. Nitric oxide production from hydroxyurea. Free Radic. Biol. Med. 2004 37 : 737 44.
75. Huang J, Kim-Shapiro DB, King SB. Catalase-mediated nitric oxide formation from hydroxyurea. J. Med. Chem. 2004 47 : 3495 501.
76. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am. J. Gastroenterol. 2000 95 : 3343 5.
77. Ou Z, Ou J, Ackerman AW, Oldham KT, Pritchard Jr KA. L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 2003 107 : 1520 4.
78. Schacter L, Warth JA, Gordon EM, Prasad A, Klein BL. Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB J. 1988 2 : 237 43.
79. Shalev O, Repka T, Goldfarb A et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995 86 : 2008 13.
80. Girgis RE, Qureshi MA, Abrams J, Swerdlow P. Decreased exhaled nitric oxide in sickle cell disease: Relationship with chronic lung involvement. Am. J. Hematol. 2003 72 : 177 84.
81. Sullivan KJ, Goodwin SR, Evangelist J, Moore RD, Mehta P. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit. Care Med. 1999 27 : 2563 8.
82. Lopez BL, Barnett J, Ballas SK, Christopher TA, Davis-Moon L, Ma X. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Acad. Emerg. Med. 1996 3 : 1098 103.
83. Zuzak KJ, Gladwin MT, Cannon III. RO, Levin IW. Imaging hemoglobin oxygen saturation in sickle cell disease patients using noninvasive visible reflectance hyperspectral techniques: Effects of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 2003 285 : H1183 9.
84. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003 289 : 1136 42.
85. Head CA, Brugnara C, Martinez-Ruiz R et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J. Clin. Invest. 1997 : 100 : 1193 8.